Clinical trials: Dementia, Mild
Dementia, Alzheimer's Disease
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
- Trial name
- NCT00104273
- Testing
- Rasagiline
- Where
- 58 sites in United States, Australia and 2 more
- Volunteers
- 376 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer Disease
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.
- Trial name
- NCT04735536
- Testing
- CT1812
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Cognition Therapeutics
Mild Cognitive Impairment
Efficacy of MEMORMAX in Subjects With MCI
This is a single-center, randomized, double-blinded placebo for the first 6 months of treatment in subjects with mild cognitive impairment.
- Trial name
- ABO-MEMO (NCT03581929)
- Testing
- Memormax
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Aboca Spa Societa' Agricola
Alzheimer's Disease
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD.
- Trial name
- NCT02423200
- Testing
- VX-745
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Alzheimer's Disease
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more…
- Trial name
- NCT05908695
- Testing
- GV-971
- Where
- 50 sites in China
- Volunteers
- 1,312 people
- Sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Mild Cognitive Impairment, Alzheimer Disease
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.
- Trial name
- NCT06400368
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- NeuroVision Imaging
Mild Cognitive Impairment, Dementia
Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment
Validate speech analysis AI models: To contrast the accuracy of acceXible's platform as a screening tool in the detection of people with cognitive impairment and mild dementia.
- Trial name
- NCT05340218
- Testing
- Speech analysis
- Where
- Spain
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Accexible
Alzheimer's Disease (AD)
Recombinant Human Serum Albumin in the Treatment of Mild-to-moderate AD (Alzheimer's Disease) Exploratory Clinical Trial
This clinical trial is an open-label, parallel-group, exploratory study of recombinant human serum albumin in patients with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT06489015
- Testing
- Recombinant Human Serum Albumin
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Protgen Co., Ltd.
Alzheimer Disease
To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
The study is designed as a classic, randomized, double blind, placebo controlled, parallel group study including one active dose of PU AD and matching placebo, designed to assess safety, tolerability and pharmacological effects…
- Trial name
- NCT04311515
- Testing
- Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers
- Where
- 10 sites in United States
- Volunteers
- 4 people
- Sponsor
- Samus Therapeutics, Inc.
Alzheimer Disease, Mild Cognitive Impairment
Software Validation Study-Cognitive Status Indicator
The SPARK Cognitive Status Indicator software uses an algorithm to assess a resting state EEG recording as being consistent with a cognitive status of unimpaired, mild cognitive impairment (MCI; MCI AD- or MCI AD+), or dementia…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- REMIND-V (NCT06809725)
- Testing
- SPARK Cognitive Status Indicator (software support data collected via EEG)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Spark Neuro Inc.
Alzheimer Disease
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
- Trial name
- NCT06995573
- Testing
- NSC001
- Where
- 10 sites in Austria, Germany
- Volunteers
- 90 people
- Sponsor
- NSC-Therapeutics
Mild to Moderate Alzheimer's Disease
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks.
- Trial name
- NCT03625622
- Testing
- AR1001
- Where
- 21 sites in United States
- Volunteers
- 210 people
- Sponsor
- AriBio Co., Ltd.
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Mild to Moderate Alzheimer's Disease
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT03507790
- Testing
- CT1812
- Where
- 32 sites in United States, Australia and 3 more
- Volunteers
- 153 people
- Sponsor
- Cognition Therapeutics
Alzheimer Disease, Mild Cognitive Impairment
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- REPHRASE (NCT05107882)
- Where
- 7 sites in United States, Canada
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.
Alzheimer's Disease, Dementia
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or…
- Trial name
- NCT01969123
- Testing
- Drug: EVP-6124
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 474 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer Disease
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
An open label pilot study in mild to moderate AD patients to assess the effects of treatment with ECHS AD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Trial name
- NCT05295615
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Herrick Medical LLC
Alzheimer´s Disease
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD).
- Trial name
- AD Biomarker (NCT07741526)
- Testing
- NPI-001
- Where
- 4 sites in Denmark, Iceland
- Volunteers
- 33 people
- Sponsor
- Arctic Therapeutics
Alzheimer's Disease, Dementia
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or…
- Trial name
- NCT01969136
- Testing
- Drug: EVP-6124
- Where
- 81 sites in United States, Argentina and 12 more
- Volunteers
- 403 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer Disease, Healthy Volunteers
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
The purpose of this study was to assess the safety, tolerability, and pharmacokinetic (PK) of TAK-071 when administered as single rising dose (SRD) and multiple rising dose (MRD) orally in healthy participants and participants…
- Trial name
- NCT02769065
- Testing
- TAK-071, Donepezil
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Takeda